

ABBREVIATED CURRICULUM VITAE

PERSONAL INFORMATION

First Name:	Kalliopi
Last Name:	Kotsa
Year of Birth:	1967

HOSPITAL ADDRESS (Current Position)

Hospital:	AHEPA University Hospital		
Clinic /Department:	Division of Endocrinology-Diabetes		
Address:	St. Kiriakidi 1		
Postal Code:	54636		
City:	Thessaloniki		
Country:	Greece		
Telephone Number:	+302310994706	Fax Number:	+302310994608
Mobile:	+306932045201		
E-mail Address:	kkalli@auth.gr		

ACADEMIC QUALIFICATIONS

Degree and / or Certification	Institution	Year of Completion
PhD in Diabetes	Aristotle University Thessaloniki	2004
MMedSci in Endocrinology, Medical Degree	University of Sheffield- Aristotle University Thessaloniki	1996 1991

PROFESSIONAL EXPERIENCE

Position held	Name of Department / Institution	Start Date – End Date
Associate Professor in Endocrinology-Diabetes	Medical School, Aristotle University Thessaloniki	5/2019 to date
Head of the Dept. Of Endocrinology-Diabetes Unit	AHEPA University Hospital, Thessaloniki, Greece	9/2014 to date
Assistant Professor in Endocrinology-Diabetes, Lecturer in Endocrinology	Medical School, Aristotle University Thessaloniki Medical School, Aristotle University Thessaloniki.	10/13-5/19 2/10-10/13

PROFESSIONAL SOCIETY MEMBERSHIPS

Endocrine Society, USA

European Society for Endocrinology (ESE)

European Association for the study of Diabetes (EASD)

Hellenic Endocrine Society (Elected as member in the Educational Committee 2018-todate)

Hellenic Diabetes Society

Diabetes Society of Northern Greece (Elected as General Secretary 2020-2023)

FOREIGN LANGUAGES

Language	Fluency / Degree
English	Excellent knowledge/ Proficiency of Cambridge/Proficiency of Michigan
French	Fluent/ Certificat de langue Francaise

GOOD CLINICAL PRACTICE (GCP)

Duration:	
Title / Content:	Investigator Site Personnel ICH GCP Training Certificate
Provider:	Lilly - TransCelerate Biofarma Inc
Training Type:	Physically Present: <input type="checkbox"/> Online training: x <input type="checkbox"/>
Date of Training Certificate:	15 May 2018

MOST CURRENT CLINICAL TRIAL EXPERIENCE

Study Name or Code	Participation Period (total in years)	Role in the study (Principal Investigator or Sub-Investigator or Study Coordinator or Other, specify)	Therapeutic Area:	Clinical Phase (Phase I, II, III, IV)	Study Status (In Progress or Closed)
I8F-MC-GPGM	2019-2021	PI	Diabetes	Phase III	In Progress
I8F-MC-GPGH	2019-2021	PI	Diabetes	Phase III	In Progress
PAR-R13-001	2019-2028	PI	Endocrinology	Phase IV	In Progress
H9X-MC-GBGL	2018-2019	PI	Diabetes	Phase III	Closed
I7I-MC-XNAA	2014-2016	PI	Diabetes	Phase II	Closed
CSOM230B2411	2016-2018	PI	Endocrinology	Phase III	Closed
I1R-MC-GLDJ	2014-2016	PI	Diabetes	Phase III	Closed

SELECTED RECENT PUBLICATIONS

Publication Date	Title / Content:
2021	Karras SN, Koufakis T, Adamidou L, Dimakopoulos G, Karalazou P, Thisiadou K, Makedou K, Kotsa K. Effects of Christian Orthodox Fasting Versus Time-Restricted Eating on Plasma Irisin Concentrations Among Overweight Metabolically Healthy Individuals. <i>Nutrients</i> . 2021 Mar 25;13(4):1071. doi: 10.3390/nu13041071.
2021	Koufakis T, Dimitriadis G, Metallidis S, Zebekakis P, Kotsa K. The role of autoimmunity in the pathophysiology of type 2 diabetes: Looking at the other side of the moon. <i>Obes Rev</i> . 2021 Mar 8:e13231. doi: 10.1111/obr.13231.
2021	Koufakis T, Grammatiki M, Kotsa K. Type 2 diabetes management in people aged over seventy-five years: targets and treatment strategies. <i>Maturitas</i> . 2021 Jan;143:118-126. doi: 10.1016/j.maturitas.2020.10.005.
2021	Kyriakidou A, Koufakis T, Goulis DG, Vasilopoulos Y, Zebekakis P, Kotsa K. Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management. <i>Curr Pharm Des</i> . 2021;27(8):1025-1034. doi: 10.2174/1381612826666201203145654.

2020	Koufakis T, Katsiki N, Zebekakis P, Dimitriadis G, Kotsa K. Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all. <i>J Diabetes</i> . 2020;12(2):110-118. doi:10.1111/1753-0407.12982
2020	Koufakis T, Mustafa OG, Ajjan RA, et al. The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking? [published online ahead of print, 2020 Jan 6]. <i>J Clin Pharm Ther</i> . 2020;10.1111/jcpt.13107. doi:10.1111/jcpt.13107
2020	Tsekmekidou X, Tsetsos F, Koufakis T, et al. Association between CUBN gene variants, type 2 diabetes and vitamin D concentrations in an elderly Greek population. <i>J Steroid Biochem Mol Biol</i> . 2020;198:105549. doi:10.1016/j.jsbmb.2019.105549
2020	Koufakis T, Mustafa OG, Zebekakis P, Kotsa K. Oral antidiabetes agents for the management of inpatient hyperglycaemia: so far, yet so close [published online ahead of print, 2020 May 23]. <i>Diabet Med</i> . 2020;10.1111/dme.14329. doi:10.1111/dme.14329
2020	Kanta A, Lyka E, Koufakis T, Zebekakis P, Kotsa K. Prevention strategies for type 1 diabetes: a story of promising efforts and unmet expectations [published online ahead of print, 2020 May 16]. <i>Hormones (Athens)</i> . 2020;10.1007/s42000-020-00207-9. doi:10.1007/s42000-020-00207-9
2020	Antonopoulou V, Karras SN, Koufakis T, et al. Rising Glucagon-Like Peptide 1 Concentrations After Parathyroidectomy in Patients With Primary Hyperparathyroidism. <i>J Surg Res</i> . 2020;245:22-30. doi:10.1016/j.jss.2019.07.019
2020	Kolokas K, Koufakis T, Avramidis I, et al. Fasting insulin levels correlate with the frequency of hypoglycemic events in people with type 2 diabetes on treatment with sulfonylureas: A pilot study. <i>Indian J Pharmacol</i> . 2020;52(1):44-48
2020	Souliotis K, Koutsovasilis A, Vatheia G, et al. Profile and factors associated with glycaemic control of patients with type 2 diabetes in Greece: results from the diabetes registry. <i>BMC Endocr Disord</i> . 2020;20(1):16. Published 2020 Jan 28. doi:10.1186/s12902-020-0496-7

Signature:

Date: / /